12:00 AM
 | 
Mar 25, 2013
 |  BioCentury  |  Emerging Company Profile

Labrys: Navigating migraine

Labrys revives Pfizer mAb to prevent chronic migraine

Labrys Biologics Inc. has picked up where Pfizer Inc. left off in developing a peripherally acting mAb for migraine. The therapeutic strategy is to hit a well-known pro-inflammatory target that turns sporadic migraine attacks into the debilitating chronic form of the disease.

Labrys' sole asset is RN-307, a mAb against calcitonin gene-related peptide (CGRP) that previously completed Phase I testing for chronic migraine. CGRP is a vasodilatory and pro-inflammatory peptide whose levels rise in the meningeal blood-brain interface during migraine onset, exacerbating pain and inflammation.

Even though RN-307 doesn't enter the brain, CMO Marcelo Bigal said hitting peripheral CGRP with the mAb blocks the pro-inflammatory signaling that leads occasional migraines to progress to the chronic condition, defined as having persistent migraine pain 14 or more times per month.

"Under normal conditions, CGRP regulates neuronal synapses and neuron interactions," said Bigal. Early in migraine, "CGRP is released at the periphery of trigeminal...

Read the full 752 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >